Furthermore, in patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), glucose-induced GLP1 secretion was significantly decreased, suggesting that down-regulation of GLP1 levels may contribute to NAFLD and NASH (18). Here, GCG is linked to metabolic dysfunction-associated steatotic liver disease.